Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. Background: IMP321 is a recombinant soluble LAG-3Ig fusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results